Commercialising a new category of care requires more than product innovation. Rebecca Windsor, Director of Veterinary Affairs at Gallant, shares how education and developing trusted continuing education platforms have been central to preparing veterinarians for the clinical adoption of regenerative medicine.

Securing non-dilutive capital can be the key to bridging the gap between research and commercial reality for agtech startups. Matt Dobbs shares how AgSenze leveraged grant programmes including Innovate UK and EU Horizon to de-risk R&D, unlock private investment, and provide a launchpad of scaling HerdVision.

When innovation moves faster than policy, the path to market calls for creative approaches. Tammie Wahaus, CEO of ELIAS Animal Health, shares how her team advances pivotal trials, adapts human health technologies, and keeps development on track as regulatory expectations continue to evolve.